Catalog No.
Product Name
Application
Product Information
Citations
-
ADC Linker
DBCO-NHS ester is a non-cleavable linker utilized in the synthesis of antibody-drug conjugates (ADCs). It serves as a click chemistry reagent, featuring a DBCO moiety that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. This compound is essential for bioconjugation applications, allowing for the stable attachment of therapeutics to antibodies, thereby enhancing the efficacy and specificity of targeted drug delivery in cancer research. -
ADC Linker
DBCO-PEG4-Maleimide is a non-cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound features a DBCO group that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, enabling efficient conjugation. It is essential for applications in targeted drug delivery, enhancing the therapeutic efficacy of ADCs while minimizing off-target effects. -
ADC/PROTAC Linker
DBCO-PEG5-NHS ester is a cleavable linker designed for use in antibody-drug conjugates (ADCs) and PROTAC synthesis. This PEG/alkyl/ether-based reagent facilitates the formation of stable covalent bonds through strain-promoted alkyne-azide cycloaddition (SPAAC), targeting azide-functionalized molecules. Its defined structure enhances the efficacy and specificity of therapeutic compounds, making it a valuable tool for researchers in the development of targeted therapies. -
ADC Linker
Gly-Gly-Gly-PEG4-DBCO is a polyethylene glycol (PEG) linker designed for use in antibody-drug conjugates (ADCs). Featuring a dibenzocyclooctyne (DBCO) functional group, this compound facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with azide-bearing compounds. Its high stability and efficiency make it an essential tool in the development of targeted therapeutics for improved delivery of cytotoxic drugs. -
ADC Linker
DBCO-Maleimide is a non-cleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). As a click chemistry reagent, it features a DBCO group that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. This property enables seamless conjugation and enhances the therapeutic efficacy of ADCs, making DBCO-Maleimide an essential tool in bioconjugation and targeted drug delivery research. -
Click Chemical Agent
DBCO-PEG24-NHS ester is a click chemistry reagent designed for selective conjugation through the reaction with primary amines, such as lysine side chains or aminosilane-coated surfaces, under neutral to slightly basic conditions. The NHS ester facilitates the formation of a stable covalent bond, while the hydrophilic PEG spacer enhances water solubility and offers a flexible linkage that reduces steric hindrance during ligation. This compound is particularly suited for applications in bioconjugation and the development of targeted delivery systems. -
ADC Linker
DBCO-Sulfo-NHS ester sodium is an efficient ADC linker designed for the synthesis of antibody-drug conjugates (ADCs), facilitating targeted drug delivery. This reagent features a DBCO group that enables strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. Its versatile coupling capabilities make it an essential tool for researchers developing novel therapeutics in cancer and other diseases. -
ADC Linker
Fluorescein-DBCO is a non-cleavable linker designed for use in the formation of antibody-drug conjugates (ADCs). This compound features a dibenzocyclooctyne (DBCO) group, enabling it to participate in strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with azide-containing molecules. Its unique properties make Fluorescein-DBCO an essential tool for researchers focusing on targeted drug delivery and cancer therapy applications through ADC development. -
ADC Linker
DBCO-Val-Cit-PABC-PNP is a cleavable linker designed for the construction of antibody-drug conjugates (ADCs). This compound features a DBCO moiety that participates in strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing substrates. Its unique structure enables precise conjugation and controlled release of cytotoxic agents, making it essential for advancing ADC research and therapeutic development. -
Azide Compound
DBCO-PEG2-NHS ester is a click chemistry reagent with an azide group, designed to facilitate bioconjugation through reactions with primary amines, such as lysine side chains or aminosilane-coated surfaces. This PEG-based compound features an NHS ester, which enables the formation of stable covalent bonds under neutral to slightly basic conditions. The hydrophilic polyethylene glycol (PEG) spacer enhances solubility and adds flexibility, reducing steric hindrance during ligation. DBCO-PEG2-NHS ester is ideal for applications in copper-free Click Chemistry and other bioconjugation studies. -
ADC Linker
DBCO-CONH-S-S-NHS ester is a cleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). Its primary mechanism involves the DBCO group, facilitating strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. This reagent plays a crucial role in the development of ADCs, allowing for targeted delivery of cytotoxic agents and enhancing therapeutic efficacy. Suitable for various applications in chemical biology and bioconjugation research. -
ADC/PROTAC Linker
DBCO-PEG4-DBCO is a PEG-based linker primarily designed for use in antibody-drug conjugates (ADCs) and PROTAC synthesis. This compound features a dibenzocyclooctyne (DBCO) group, facilitating strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. Its versatile reactivity enables the development of targeted therapeutics, enhancing specificity and efficacy in research applications focused on protein degradation and targeted delivery systems. -
ADC Linker
DBCO-PEG3-oxyamine is a non-cleavable linker specifically designed for antibody-drug conjugate (ADC) synthesis. Featuring a DBCO moiety, this reagent facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with azide-containing molecules. Its application in conjugating antibodies to therapeutic agents enhances targeted delivery and efficacy in cancer research and drug development. -
ADC Linker
DBCO-Sulfo-Link-biotin is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). It features a DBCO moiety that enables efficient strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing compounds. This reagent is valuable in the development of targeted therapies, facilitating precise delivery of cytotoxic agents to tumor cells while minimizing off-target effects. Its application enhances the effectiveness of therapeutic strategies in oncology and related fields. -
ADC Linker
DBCO-NHCO-S-S-NHS ester is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound contains a DBCO group, facilitating strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. Its application is crucial in the construction of targeted therapies, enabling the selective delivery of cytotoxic agents to specific cells. -
ADC Linker
DBCO-C6-acid is a non-cleavable ADC linker that facilitates the formation of antibody-drug conjugates (ADCs). Its unique DBCO moiety allows for efficient strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing compounds. This reagent is particularly useful in the synthesis of carmaphycin analogues, enabling targeted delivery of therapeutic agents for enhanced efficacy in research applications related to targeted cancer therapies. -
ADC/PROTAC Linker
DBCO-PEG4-amine is a PEG-based linker designed for use in the synthesis of PROTACs and antibody-drug conjugates (ADCs). This versatile cleavable linker allows for efficient conjugation through its DBCO group, enabling strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with azide-containing molecules. Its applications extend to the creation of homobifunctional cross-linkers, such as FPM-PEG4-DBCO, facilitating advanced drug delivery and targeted degradation strategies in chemical biology research. -
Cycloalkynes Compound
Cy5.5 DBCO is a cycloalkyne-based click chemistry reagent featuring a cyanine 5.5 fluorophore. The presence of the DBCO moiety facilitates copper-free, biocompatible click reactions characterized by rapid kinetics and enhanced stability. This reagent is widely utilized in bioconjugation applications, enabling efficient labeling of biomolecules for imaging and detection in various biological studies. -
ADC Linker
DBCO-PEG2-DBCO is a versatile click chemistry reagent featuring two terminal dibenzocyclooctyne (DBCO) groups connected by a polyethylene glycol (PEG) linker. This compound is engineered for efficient, copper-free click reactions, making it particularly valuable in the development of antibody-drug conjugates (ADCs). Its unique chemical properties promote strong and selective labeling, enabling researchers to explore novel therapeutic applications and enhance drug delivery systems in biomedical research. This reagent is intended for research use only. -
ADC Linker
DBCO-PEG2-Val-Cit-PAB-MMAE is an antibody-drug conjugate (ADC) linker that employs a DBCO group for efficient click chemistry with azide moieties. This reagent incorporates a Val-Cit dipeptide, which is cleavable by proteases, facilitating the targeted release of the MMAE warhead within cells through an elimination mechanism. Its design is optimized for applications in targeted cancer therapy, enhancing the specificity and efficacy of drug delivery systems. -
ADC Linker
DBCO-PEG4-Val-Cit-PAB-PNP is a cleavable ADC linker that facilitates targeted drug delivery. The Val-Cit moiety is specifically cleaved by Cathepsin B, enabling the release of an amine-containing payload when substituted. The DBCO group allows for efficient click chemistry with azide-bearing compounds, making this linker suitable for various antibody-drug conjugate applications in therapeutic research. -
ADC Linker
DBCO-PEG3-acid is a non-cleavable ADC linker featuring a 3-unit polyethylene glycol (PEG) chain. Its primary mechanism involves the strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, enabling effective conjugation in the synthesis of antibody-drug conjugates (ADCs). This reagent is particularly valuable in therapeutic research applications, facilitating targeted drug delivery and enhancing the pharmacological properties of antibody-based treatments. -
ADC Linker
DBCO-PEG24-Maleimide is a versatile linker featuring a maleimide group and a DBCO (dibenzocyclooctyne) moiety. This compound is ideal for conjugating thiol-containing biomolecules and facilitates efficient click chemistry reactions with azide-bearing substrates. Its unique structure enables stable linkages, making it suitable for applications in antibody-drug conjugates (ADCs) and other bioconjugation frameworks in chemical biology research. -
ADC Linker
DBCO-PEG4-Val-Ala-PAB-PNP is a cleavable antibody-drug conjugate (ADC) linker designed for targeted delivery applications. The Val-Ala sequence enables selective cleavage by Cathepsin B, facilitating the release of the therapeutic payload. The incorporation of a PEG spacer enhances aqueous solubility, while the DBCO group is suitable for Click Chemistry reactions due to its reactivity. Additionally, the PNP moiety serves as an efficient leaving group, making this compound valuable in bioconjugation and therapeutic development. -
ADC Linker
Methyltetrazine-DBCO is a non-cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound features a DBCO group that enables strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. Additionally, the inclusion of a tetrazine moiety allows for inverse electron demand Diels-Alder reactions (iEDDA) with trans-cyclooctene (TCO) compounds. Methyltetrazine-DBCO is an essential reagent for researchers developing targeted therapies through click chemistry methodologies. -
Fluorescent Dye
Cy5-DBCO is a near-infrared fluorescent dye that features an absorption maximum at 646 nm and emission maximum at 670 nm. This compound functions as a click chemistry reagent, containing a DBCO group that readily participates in strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. It is particularly useful in bioconjugation applications, facilitating the labeling of proteins and other biomolecules for imaging and tracking studies, although it is not recommended for staining intracellular components in permeabilized cells due to potential high background. -
Orange Fluorescent Dye
DBCO-Cy3 is an orange fluorescent dye derived from the Cyanine3 fluorophore, exhibiting stable fluorescence across a pH range of 4-10. It has an excitation maximum at 555 nm and an emission maximum at 580 nm, making it suitable for various fluorescence applications. DBCO-Cy3 features rapid reaction kinetics and is compatible with standard fluorescence instruments. As a click chemistry reagent, it contains a DBCO group that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, enabling targeted labeling and imaging in biochemical research. -
Dye Reagent
DBCO-PEG12-TCO is a dual-functional click chemistry reagent featuring both DBCO and TCO moieties. The DBCO group enables strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-bearing molecules, while the TCO moiety is capable of engaging in inverse electron demand Diels-Alder (iEDDA) reactions with tetrazine-containing compounds. This reagent is suitable for applications in bioconjugation, drug discovery, and the development of functionalized biomolecules in chemical biology research. -
BG-JQ1 Intermediate
BG-DBCO is a DBCO-conjugated benzylguanine that serves as an essential intermediate for synthesizing BG-JQ1. This compound forms a complex with SNAP-E3 fusion protein and Ligand-N3, facilitating targeted applications in cellular research. BG-JQ1, derived from the conjugation of BG-DBCO with JQ1-N3-C10, has demonstrated potent inhibitory effects on the growth of small cell carcinoma of the adrenocortical gland when administered alongside SIAH1-SN mRNA. This reagent is invaluable for studies aimed at understanding and targeting cancer cell proliferation pathways. -
NIR Fluorescent Dye
Cyanine7 DBCO is a near-infrared fluorescent dye that acts as an efficient bio-orthogonal quencher. It is generated through the covalent linkage of the Cy7 fluorescent dye and the dibenzocyclooctyne (DBCO) moiety. In biochemical applications, Cyanine7 DBCO significantly decreases the fluorescence of N3-Cy5-COOH by 90% within 90 minutes, with observable signal reduction occurring as quickly as 2-5 minutes. This reagent is ideal for deep tissue imaging and advancing receptor-targeted therapeutic strategies in chemical research. -
Azide Reactive Probe
Cyanine3 DBCO hexafluorophosphate is an azide-reactive probe designed for bioconjugation applications through copper-free "click" chemistry. It enables selective and efficient labeling of azide-functionalized biomolecules, making it an invaluable tool for imaging and analyzing cellular processes. This reagent is particularly useful in studies involving bioorthogonal chemistry and can facilitate the visualization of complex biomolecular interactions. -
Azide Reaction Probe
Cyanine 5 DBCO is an azide-reactive probe that facilitates copper-free "click" reactions for the imaging of azide-labeled biomolecules. This near-infrared (NIR) fluorescent dye exhibits low toxicity and does not adversely affect the physiological functions of non-target cells. With excitation at 635 nm and emissions ranging from 650 to 700 nm, Cyanine 5 DBCO is suitable for labeling and tracking cells in both in vitro and in vivo research applications. -
Fluorescent Dye
5-TAMRA-DBCO is a fluorescent dye featuring a 5-TAMRA core conjugated to a dibenzocyclooctyne (DBCO) moiety. This compound enables efficient copper-free click chemistry reactions with azide-functionalized biomolecules, facilitating precise bioconjugation. With emission and excitation wavelengths of 541 nm and 567 nm, respectively, 5-TAMRA-DBCO is ideal for labeling proteins, peptides, and nucleic acids, making it a valuable tool for various biological imaging and analysis applications. -
Drug-Linker Conjugate for ADC
DBCO-PEG4-VC-PAB-MMAE is a conjugate designed for use in antibody-drug conjugate (ADC) synthesis, incorporating a drug-linker element. The DBCO component facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with azide-containing molecules. The included MMAE moiety, a potent inhibitor of tubulin polymerization derived from dolastatin 10, exhibits significant mitotic inhibition. This reagent is ideal for advancing research in targeted cancer therapies by enabling the precise delivery of cytotoxic agents to tumor cells. -
Drug-Linker Conjugates for ADC
DBCO-PEG4-GGFG-Dxd is a drug-linker conjugate targeting antibody-drug conjugates (ADCs) with potent antitumor activity derived from the DNA topoisomerase I inhibitor Dxd. This compound utilizes a cleavable linker, DBCO-PEG4-GGFG, which enhances selective delivery of the therapeutic agent. DBCO-PEG4-GGFG-Dxd serves as a click chemistry reagent, featuring a DBCO moiety that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, making it a valuable tool in bioconjugation applications. -
Drug-Linker Conjugates for ADC
DBCO-PEG4-Val-Cit-PAB-MMAF is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs) that combines a cleavable PEG linker with the potent tubulin polymerization inhibitor MMAF. The DBCO moiety facilitates efficient synthesis through click chemistry, specifically strain-promoted alkyne-azide cycloaddition (SPAAC), allowing for precise conjugation to azide-containing biomolecules. This reagent is essential for enhancing the therapeutic efficacy of ADCs by enabling targeted delivery of cytotoxic agents. -
Drug-Linker Conjugate for ADC
DBCO-PEG4-MMAF is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, utilizing MMAF as a potent tubulin polymerization inhibitor. The conjugate features a cleavable linker, DBCO-PEG4, which facilitates the selective release of MMAF within target cells. DBCO-PEG4-MMAF serves as a click chemistry reagent, containing a DBCO group that efficiently engages in strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-modified molecules, making it a valuable tool for targeted therapeutics in cancer research. -
Drug-Linker Conjugates for ADC
DBCO-(PEG2-VC-PAB-MMAE)2 is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound features Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, linked to a cleavable DBCO-(PEG2-VC-PAB)2 linker. The DBCO group enables efficient strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, facilitating targeted delivery of cytotoxic agents. Its application is crucial for research in cancer therapeutics, particularly in enhancing the efficacy and selectivity of ADCs. -
Drug-Linker Conjugate for ADC
DBCO-(PEG)3-VC-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). This compound features Monomethyl auristatin E (MMAE) linked to a DBCO-(PEG)3-VC-PAB structure, facilitating targeted drug delivery in cancer research. As a click chemistry reagent, it utilizes a DBCO group that enables strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, making it valuable in bioconjugation applications. -
Drug-Linker Conjugate for ADC
DBCO-PEG3-VC-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound combines the DBCO-PEG3-VC linker with Exatecan, a potent inhibitor of DNA topoisomerase I. Its structure facilitates targeted delivery of the cytotoxic agent to cancer cells, enhancing therapeutic efficacy while minimizing off-target effects. Research applications include the development of ADCs for cancer treatment, providing a strategic tool for targeted therapy and molecular oncology studies. -
Drug-Linker Conjugates for ADC
DBCO-PEG4-VA-PBD is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound utilizes the potent antitumor antibiotic Pyrrolobenzodiazepine (PBD), which is linked via a DBCO-PEG4-VA spacer. DBCO-PEG4-VA-PBD acts as a click chemistry reagent, featuring a DBCO moiety that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. This functionality supports the development of targeted therapies for cancer treatment, enhancing the efficacy of ADCs. -
ADC Drug-Linker Conjugate
DBCO-Val-Cit-PAB-MMAE is an ADC drug-linker conjugate designed for the synthesis of antibody-drug conjugates (ADCs). It incorporates the tubulin inhibitor MMAE, which acts as a cytotoxic agent targeting rapidly dividing cells. The DBCO-Val-Cit-PAB linker features an electrophilic group, facilitating stable conjugation to antibodies and enhancing the therapeutic efficacy of ADCs in cancer research applications. -
Drug-Linker Conjugate for ADC
DBCO-PEG4-VC-PAB-DMEA-PNU-159682 is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). It combines the DBCO-PEG4-VC-PAB linker with the potent cytotoxin DMEA-PNU-159682, which includes active metabolites of nemorubicin. This compound leverages click chemistry, featuring a DBCO group that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. DBCO-PEG4-VC-PAB-DMEA-PNU-159682 serves as an effective tool in targeted cancer therapy research and the development of innovative ADCs. -
Drug-Linker Conjugate for ADC
DBCO-β-Glu-PEG12-Exatecan serves as a drug-linker conjugate specifically designed for antibody-drug conjugates (ADCs). This compound acts as a potent inhibitor of topoisomerase I, effectively disrupting DNA replication and transcription processes. Its unique structure allows for targeted delivery in therapeutic applications, making it suitable for research in cancer treatment and other malignancies. This reagent provides a valuable tool for the development and optimization of ADC formulations. -
Drug-Linker Conjugate for ADC
DBCO-PEG4-VA-PABC-MMAE is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). It features a potent tubulin inhibitor, MMAE, linked via a cleavable moiety, DBCO-PEG4-VA-PABC, facilitating targeted delivery to cancer cells. This conjugate is suitable for the synthesis of ADCs, demonstrating potential application in targeted cancer therapies by enhancing therapeutic efficacy while minimizing systemic toxicity. -
Anticancer Agent
DBCO-PEG3-GGFG-Exatecan is a drug-linker conjugate designed for use in antibody-drug conjugate (ADC) applications. This compound features the DBCO-PEG3-GGFG linker combined with Exatecan, a potent DNA topoisomerase I inhibitor. It is engineered to enhance the targeted delivery of cytotoxic agents to cancer cells, thereby improving therapeutic efficacy. DBCO-PEG3-GGFG-Exatecan is suited for research in cancer biology and the development of novel treatment strategies. -
Drug-Linker Conjugate
DBCO-PEG4-Ahx-DM1 is a drug-linker conjugate that incorporates the potent microtubulin inhibitor DM1, designed to facilitate antibody-drug conjugate (ADC) development. DM1, a maytansinoid, targets microtubules to inhibit cancer cell proliferation while minimizing systemic toxicity. The DBCO moiety in this compound allows for strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing biomolecules, enabling efficient conjugation for targeted delivery in cancer research applications. -
Drug-linker Conjugate for ADC
DBCO-PEG3-Glu-VC-PABC-MMAF is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). It features the tubulin inhibitor MMAF linked through a cathepsin cleavable DBCO-PEG3-Glu-VC-PABC moiety, facilitating targeted delivery of the cytotoxic agent. This compound is valuable for research applications focusing on the development of ADCs, enabling studies on efficacy, mechanism of action, and therapeutic potential in cancer treatment. -
Drug-linker Conjugate
DBCO-PEG3-Glu-Val-Cit-PABC-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound incorporates the potent tubulin inhibitor Monomethyl auristatin E (MMAE), facilitating targeted delivery in cancer therapeutics. Its structural features enable effective synthesis of dual-drug ADCs, enhancing cytotoxic efficacy while minimizing off-target effects. -
Bifunctional Chelating Agent
Deferoxamine-DBCO is a bifunctional chelating agent that effectively binds to radioactive metals, such as 89Zr, via its deferoxamine (DFO) structure for radiolabeling applications. Additionally, it facilitates metal-free Huisgen cycloaddition reactions with azide-containing biomolecules, including siRNA and monoclonal antibodies, through its dibenzocyclooctyne (DBCO) moiety under bioorthogonal conditions. This reagent combines robust metal-chelating capabilities with specific bioorthogonal reactivity, making it suitable for targeted radioactive imaging studies in oncology research.
